The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
The involvement of gut microbiota in inflammatory bowel disease pathogenesis: Potential for therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation
Arpaia, N., Campbell, C., Fan, X., Dikiy, S., van der Veeken, J., deRoos, P., Liu, H., Cross, J. R., Pfeffer, K., Coffer, P. J., et al. (2013) · Nature · doi:10.1038/nature12726 · Cited by 4,838 · cited 1×
“SCFAs are bacterial metabolites that regulate development and function of colonic Tregs, via immune and non-immune cells (Arpaia et al., 2013; Smith et al., 2013).”
BackgroundSokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182
Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species
Atarashi, K., Tanoue, T., Shima, T., Imaoka, A., Kuwahara, T., Momose, Y., Cheng, G., Yamasaki, S., Saito, T., Ohba, Y., et al. (2011) · Science · doi:10.1126/science.1198469 · Cited by 3,752 · cited 4×
“Commensal microbes, such as Bacteroides fragilis and bacteria belonging to Clostridium cluster IV, have anti-inflammatory properties via Treg induction (Atarashi et al., 2011; Martin et al., 2014; Round et al., 2011; Sokol et al., 2008; Sokol et al., 2009).”
BackgroundInfluentialThe gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681
Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota
Atarashi, K., Tanoue, T., Oshima, K., Suda, W., Nagano, Y., Nishikawa, H., Fukuda, S., Saito, T., Narushima, S., Hase, K., et al. (2013) · Nature · doi:10.1038/nature12331 · Cited by 2,872
Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach
Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P., Marteau, P., et al. (2006) · Gut · doi:10.1136/gut.2005.073817 · Cited by 2,277
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256
The Long-Term Stability of the Human Gut Microbiota
Faith, J. J., Guruge, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., Clemente, J. C., Knight, R., Heath, A. C., Leibel, R. L., et al. (2013) · Science · doi:10.1126/science.1237439 · Cited by 2,058
Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.-L., Barnich, N., Bringer, M.-A., Swidsinski, A., Beaugerie, L., & Colombel, J.-F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.061 · Cited by 1,566
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548 · cited 3×
“#3 probiotc mixture; additionally, among probiotics only E. coli Nissle 1917 has been suggested as an effective alternative to mesalazine for the maintenance of remission of UC (Dignass et al. 2012).”
BackgroundInfluentialBesselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367 · cited 1×
“In severe acute pancreatitis, as shown by a large double-blind randomized controlled trial, probiotic prophylaxis was not effective in reducing the risk of infections, being instead associated with an increased risk of mortality (Besselink et al., 2008).”
BackgroundOtt, S. J., Musfeldt, M., Wenderoth, D. F., Hampe, J., Brant, O., Fölsch, U. R., Timmis, K. N., & Schreiber, S. (2004) · Gut · doi:10.1136/gut.2003.025403 · Cited by 1,311
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285 · cited 1×
“In four randomized clinical trials, it was found as effective and safe as mesalazine in the maintenance of remission in patients with UC (Henker et al., 2008; Kruis et al., 1997; Kruis et al., 2004; Rembacken et al., 1999).”
BackgroundLymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis
Bouskra, D., Brézillon, C., Bérard, M., Werts, C., Varona, R., Boneca, I. G., & Eberl, G. (2008) · Nature · doi:10.1038/nature07450 · Cited by 1,107
ATP drives lamina propria TH17 cell differentiation
Atarashi, K., Nishimura, J., Shima, T., Umesaki, Y., Yamamoto, M., Onoue, M., Yagita, H., Ishii, N., Evans, R., Honda, K., et al. (2008) · Nature · doi:10.1038/nature07240 · Cited by 1,089 · cited 1×
“In murine models, Th17 cells are also induced by luminal adenosine triphosphate produced by the microbiota and by serum amyloid A proteins produced by epithelial cells after segmented filamentous bacteria (SFB) colonization (Atarashi et al 2008, Ivanov et al., 2009).”
BackgroundDysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives
Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme, P., & Vermeire, S. (2011) · Gut · doi:10.1136/gut.2010.223263 · Cited by 1,063
Willing, B. P., Dicksved, J., Halfvarson, J., Andersson, A. F., Lucio, M., Zheng, Z., Järnerot, G., Tysk, C., Jansson, J. K., & Engstrand, L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.049 · Cited by 1,032
The genetics and immunopathogenesis of inflammatory bowel disease
Cho, J. H. (2008) · Nature Reviews Immunology · doi:10.1038/nri2340 · Cited by 940
Kassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904
Safety assessment of probiotics for human use
Sanders, M. E., Akkermans, L. M. A., Haller, D., Hammerman, C., Heimbach, J. T., Hörmannsperger, G., & Huys, G. (2010) · Gut Microbes · doi:10.4161/gmic.1.3.12127 · Cited by 816
Probiotic use in clinical practice: what are the risks?
Boyle, R. J., Robins-Browne, R. M., & Tang, M. L. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.6.1256 · Cited by 776
Furrie, E., Macfarlane, S., Kennedy, A., Cummings, J. H., Walsh, S. V., O’Neil, D. A., & Macfarlane, G. T. (2005) · Gut · doi:10.1136/gut.2004.044834 · Cited by 766 · cited 1×
“…of B. longum and Sinergy 1 (a inulinoligofructose substrate) was evaluated in patients with active UC as an adjunct to medical treatment in a small randomized, placebo-controlled trial, showing a trend (P=0.06) of benefit over placebo in improving clinical activity index (Furrie et al., 2005).”
MethodInfluentialShould we standardize the 1,700-year-old fecal microbiota transplantation?
Zhang, F., Luo, W., Shi, Y., Fan, Z., & Ji, G. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.251 · Cited by 619
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513 · cited 1×
“#3 probiotic mixture, administered for 6-12 weeks, in inducing the remission in patients with mildly-to-moderately active UC treated with conventional therapy (Bibiloni et al., 2005; Tursi et al., 2004; Tursi et al., 2010) or not receiving any other therapy (Lee et al., 2012; Sood et al., 2009).”
BackgroundTursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489 · cited 1×
“#3 probiotic mixture, administered for 6-12 weeks, in inducing the remission in patients with mildly-to-moderately active UC treated with conventional therapy (Bibiloni et al., 2005; Tursi et al., 2004; Tursi et al., 2010) or not receiving any other therapy (Lee et al., 2012; Sood et al., 2009).”
BackgroundSelf-citationProbiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482 · cited 1×
“…mucin-secreting goblet cells and the evidence of leaking tight junctions) have been shown in germ-free animals in comparison to conventional animals (Bouskra et al., 2008; Durkin et al., 1981; Gordon et al., 1966; Hamada et al., 2002; Ukena et al. 2007; for a review, see Nagalingam et al., 2012).”
BackgroundLindsay, J. O. (2006) · Gut · doi:10.1136/gut.2005.074971 · Cited by 471
The Commensal Microbiota and Enteropathogens in the Pathogenesis of Inflammatory Bowel Diseases
Chassaing, B., & Darfeuille–Michaud, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.054 · Cited by 443
Cammarota, G., Ianiro, G., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000046 · Cited by 428
Self-citationKato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02268.x · Cited by 397 · cited 2×
“However, the second study did not confirm such good outcomes at all, since no significant differences were found between the two groups in terms of clinical and endoscopic activity indices and histology scores (Kato et al., 2004).”
MethodResultGut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease
Conte, M. P., Schippa, S., Zamboni, I., Penta, M., Chiarini, F., Seganti, L., Osborn, J., Falconieri, P., Borrelli, O., & Cucchiara, S. (2006) · Gut · doi:10.1136/gut.2005.078824 · Cited by 383
Invasive Saccharomyces Infection: A Comprehensive Review
Enache-Angoulvant, A., & Hennequin, C. (2005) · Clinical Infectious Diseases · doi:10.1086/497832 · Cited by 369 · cited 1×
“In addition, sepsis by S. boulardii, which is used in probiotic preparations to treat some types of diarrhoea, accounted for 51.3% of total fungaemias in a large French cohort (Enache-Angoulvant & Hennequin, 2005).”
BackgroundInfluentialA systematic review of the safety of probiotics
Didari, T., Solki, S., Mozaffari, S., Nikfar, S., & Abdollahi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.872627 · Cited by 367 · cited 2×
“available systematic reviews of the literature agree on the partial, but not total, safety of probiotics (Didari et al., 2014; Whelan & Myers, 2010).”
BackgroundShen, J., Zuo, Z.-X., & Mao, A.-P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000437495.30052.be · Cited by 364
Benjamin, J. L., Hedin, C. R. H., Koutsoumpas, A., Ng, S. C., McCarthy, N. E., Hart, A. L., Kamm, M. A., Sanderson, J. D., Knight, S. C., Forbes, A., et al. (2011) · Gut · doi:10.1136/gut.2010.232025 · Cited by 361 · cited 1×
“A larger placebo-controlled clinical trial, however, did not confirm these results (Benjamin et al., 2011).”
ResultDesulfovibrio Bacterial Species Are Increased in Ulcerative Colitis
Rowan, F., Docherty, N. G., Murphy, M., Murphy, B., Coffey, J. C., & O‘Connell, P. R. (2010) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181f1e620 · Cited by 333
Angelberger, S., Reinisch, W., Makristathis, A., Lichtenberger, C., Dejaco, C., Papay, P., Novacek, G., Trauner, M., Loy, A., & Berry, D. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.257 · Cited by 330 · cited 8×
“Only few, more recent studies used objective scores to assess the disease activity (Angelberger et al., 2013; Kump et al., 2013; Kunde et al., AC C EP TE D M AN U SC R IP T 2013; Landy et al., 2013; Vaandeplas et al., 2014).”
BackgroundMethodResultInfluentialScanlan, P. D., Shanahan, F., O'Mahony, C., & Marchesi, J. R. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00312-06 · Cited by 330
Role of the microbiota in inflammatory bowel diseases
Nagalingam, N. A., & Lynch, S. V. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21866 · Cited by 315
Kunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292fa0d · Cited by 314 · cited 2×
“…Helicobacteraceae family and of enterohepatic Helicobacter spp. has been described in pediatric (Man et al., 2008; Kaakoush et al., 2010) and adult (Laharie et al., 2009) patients with CD, in adult patients with UC (Thomson et al., 2011), in mixed pediatric cohorts (Zhang et al., 2006), and in…”
BackgroundVieira, E. L. M., Leonel, A. J., Sad, A. P., Beltrão, N. R. M., Costa, T. F., Ferreira, T. M. R., Gomes-Santos, A. C., Faria, A. M. C., Peluzio, M. C. G., Cara, D. C., et al. (2012) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.01.007 · Cited by 290
Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J.-J., Sokol, H., Verdu, E. F., Bercik, P., Bermúdez-Humarán, L. G., & Langella, P. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000440815.76627.64 · Cited by 284
Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S., Reicht, G., Hoffmann, K. M., Deutschmann, A., Wenzl, H. H., Petritsch, W., Krejs, G. J., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e31829ea325 · Cited by 235
Borody, T. J., George, L., Andrews, P., Brandl, S., Noonan, S., Cole, P., Hyland, L., Morgan, A., Maysey, J., & Moore‐Jones, D. (1989) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb136704.x · Cited by 221
Regulatory Oversight and Safety of Probiotic Use
Venugopalan, V., Shriner, K. A., & Wong-Beringer, A. (2010) · Emerging Infectious Diseases · doi:10.3201/eid1611.100574 · Cited by 216 · cited 1×
“5.2.3 Probiotics, prebiotics, synbiotics for inflammatory bowel disease: potential adverse events Both the U.S. Food and Drug Administration (FDA) and the European Food Safety Authority classify probiotics as food supplements (Venugopalan et al., 2010; Von Wright, 2005).”
BackgroundInfluentialDe Leon, L. M., Watson, J. B., & Kelly, C. R. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.04.045 · Cited by 215 · cited 1×
“…of quiescent UC was observed in a subject undergoing FMT for recurrent C. difficile infection; endoscopic assessment before and after the transplant allowed the authors to reasonably define the colonic inflammation as an adverse event rather than a lack of clinical response (De Leon et al., 2013).”
BackgroundUnstable Composition of the Fecal Microbiota in Ulcerative Colitis During Clinical Remission
Martinez, C., Antolin, M., Santos, J., Torrejon, A., Casellas, F., Borruel, N., Guarner, F., & Malagelada, J.-R. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01592.x · Cited by 208
Clayton, E. M., Rea, M. C., Shanahan, F., Quigley, E. M. M., Kiely, B., Hill, C., & Ross, R. P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.4 · Cited by 202
Ishikawa, H., Matsumoto, S., Ohashi, Y., Imaoka, A., Setoyama, H., Umesaki, Y., Tanaka, R., & Otani, T. (2011) · Digestion · doi:10.1159/000322977 · Cited by 197 · cited 1×
“Additionally, a one-year supplementation of anti-inflammatory therapy (steroids and salicylates) with a synbiotic composed of B. breve strain Yakult and galactooligosaccharide resulted in a significant endoscopic score improvement in patients with mild-tomoderate active UC (Ishikawa et al. 2011).”
BackgroundManipulation of the Microbiota for Treatment of IBS and IBD—Challenges and Controversies
Shanahan, F., & Quigley, E. M. M. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.050 · Cited by 172
Whelan, K., & Myers, C. E. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28759 · Cited by 161 · cited 1×
“Several studies were carried out to fill this gap, and the available systematic reviews of the literature agree on the partial, but not total, safety of probiotics (Didari et al., 2014; Whelan & Myers, 2010).”
BackgroundMukhopadhya, I., Thomson, J. M., Hansen, R., Berry, S. H., El-Omar, E. M., & Hold, G. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021490 · Cited by 145
Policy: how to regulate faecal transplants
Smith, M. B., Kelly, C., & Alm, E. J. (2014) · Nature · doi:10.1038/506290a · Cited by 140 · cited 1×
“Thus, regulation of FMT has been advocated (Smith et al., 2014), and FDA has recently driven efforts in that direction (Mole, 2013).”
BackgroundNatividad, J. M. M., Petit, V., Huang, X., de Palma, G., Jury, J., Sanz, Y., Philpott, D., Garcia Rodenas, C. L., McCoy, K. D., & Verdu, E. F. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22848 · Cited by 139
Russell, G. H., Kaplan, J. L., Youngster, I., Baril‐Dore, M., Schindelar, L., Hohmann, E., & Winter, H. S. (2014) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000000283 · Cited by 64
Vermeire, S., Joossens, M., Verbeke, K., Hildebrand, F., Machiels, K., Van den Broeck, K., Van Assche, G., Rutgeerts, P. J., & Raes, J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)61356-0 · Cited by 63
Landy, J., Al-Hassi, H. O., Mann, E. R., Peake, S. T., McLaughlin, S. D., Ciclitira, P. J., Clark, S. K., Knight, S. C., & Hart, A. L. (2013) · Gastroenterology · doi:10.1016/s0016-5085(13)63341-7 · Cited by 19
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Benefaction of probiotics for human health: A review
George Kerry, R., Patra, J. K., Gouda, S., Park, Y., Shin, H.-S., & Das, G. (2018) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2018.01.002 · Cited by 898
Mechanisms and consequences of intestinal dysbiosis
Weiss, G. A., & Hennet, T. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2509-x · Cited by 775
Antibiotics as deep modulators of gut microbiota: between good and evil
Ianiro, G., Tilg, H., & Gasbarrini, A. (2016) · Gut · doi:10.1136/gutjnl-2016-312297 · Cited by 625
Self-citationPain regulation by gut microbiota: molecular mechanisms and therapeutic potential
Guo, R., Chen, L.-H., Xing, C., & Liu, T. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.07.026 · Cited by 405
Metadata
- Authors
- Cammarota, G., Ianiro, G., Cianci, R., Bibbò, S., Gasbarrini, A., & Currò, D.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 149
- Pages
- 191-212
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2011168613
- Cited by
- 180
- References
- 63
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.